Dimerix's DMX-200 Advances in Phase 3 FSGS Trial with Strong Safety Profile and FDA-Aligned Endpoint Data
核心洞察
Dimerix (搜索)'s Phase 3 ACTION3 trial for DMX-200 in focal segmental glomerulosclerosis (搜索) (FSGS (搜索)) has successfully completed its seventh Independent Data Monitoring Committee safety review with no concerns raised.
New PARASOL (搜索) collaboration data reinforces the use of proteinuria (搜索)-based endpoints for the pivotal study, aligning with FDA guidance for accelerated approval pathways in this rare kidney disease (搜索).
The trial has randomized 271 patients as of November 2024, with DMX-200 demonstrating consistent tolerability across all safety assessments in this underserved patient population.
Dimerix (搜索) has reported significant progress in its pivotal Phase 3 ACTION3 study of DMX-200 for focal segmental glomerulosclerosis (搜索) (FSGS (搜索)), with the seventh Independent Data Monitoring Committee (IDMC) review clearing the trial to continue unchanged and new international data supporting the study's regulatory strategy.
Safety Profile Reinforced Through Seventh IDMC Review
The latest IDMC evaluation, completed in accordance with international good clinical practice guidelines, found no safety concerns with DMX-200, reinforcing the drug's emerging safety profile. As of November 18, 2024, the ACTION3 study had randomized or dosed 271 patients, including three pediatric participants.
"The IDMC's recommendation underscores the strong and emerging safety profile of DMX-200," said Dr. David Fuller, Dimerix (搜索)'s chief medical officer. "This positions DMX-200 as a potential compelling asset in the FSGS (搜索) treatment landscape, offering meaningful hope to patients with limited options and representing a significant commercial opportunity in an underserved market."
The committee's recommendation to continue the trial unchanged marks the seventh consecutive positive safety assessment, with the next IDMC meeting scheduled for the second quarter of 2026.
PARASOL Data Supports Regulatory Strategy
Dimerix (搜索) has received final data analysis from the international PARASOL (搜索) collaboration that reinforces support for proteinuria (搜索)-based endpoints in the ACTION3 study. The analysis explored the relationship between proteinuria and estimated glomerular filtration rate (eGFR) endpoints at 12 and 24 months, along with subsequent kidney failure risk.
The results align with a previous 2024 analysis that supported the use of proteinuria (搜索) as an endpoint for FSGS (搜索) clinical trials. Dimerix (搜索) plans to incorporate this new data into its FDA application for accelerated approval.
"The findings are a testament to the collaborative nature of the PARASOL (搜索) group and we look forward to discussing them with the FDA in due course," Fuller noted.
Trial Design and Patient Population
ACTION3 is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study evaluating DMX-200's efficacy and safety in FSGS (搜索) patients who remain on stable doses of angiotensin II receptor blockers (ARBs). Once the ARB (搜索) dose is stabilized, patients receive either 120 milligrams of DMX-200 twice daily or placebo.
The single global trial includes two interim analyses to assess reductions in proteinuria (搜索) and changes in kidney function, generating evidence required for regulatory approval in major markets.
Addressing Unmet Medical Need
FSGS (搜索) is a rare and serious kidney disorder characterized by progressive scarring in parts of the glomeruli, the kidney's filtering units, leading to proteinuria (搜索) and end-stage renal disease (搜索). Research increasingly suggests FSGS has an inflammatory component, with estimates indicating more than 40,000 adults and children in the US are impacted by the condition.
The FDA confirmed in April that suitable proteinuria (搜索) primary endpoints could include either the proportion of patients achieving defined proteinuria reduction compared to placebo, or the percentage change in proteinuria from baseline after two years of treatment.